Suramin-induced neutropenia

European Journal of Cancer Part A

Volumn 32, Issue 9, 1996, Pages 1523-1529

  Dawson, N A ^a   Lush, R M ^b   Steinberg, S M ^c   Tompkins, A C ^c   Headlee, D J ^a   Figg, W D ^b  

^a Clinical Pharmacology Branch   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

Author keywords

Granulocyte colony stimulating factor; Neutropenia; Prostatic neoplasms; Suramin; Toxicity

Indexed keywords

EID: 33748464401     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Myers C, Cooper M, Stein C, et al, Suramin: a novel growth factor antagonist with activity in hormone-refractory prostate cancer. JC/m Oncol 1992, 10, 881-889.
2. La Rocca RV, Stein CA, Myers CE. Suramin: prototype of a new generation of antitumor compounds. Cancer Cells 1990, 2, 106-115.
3. Stein CA. Suramin: a novel antineoplastic agent with multiple potential mechanisms of action. Cancer Res 1993, 53, 2239-2248.
4. Middaugh CR, Mach H, Burke Cj, et al. Nature of the interaction of growth factors with suramin. Biochemistry 1992, 31, 9016-9024.
5. Dawson NA, Cooper MR, Figg WD, et al. Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer 1995, 76, 453-462.
6. Cooper MR, Lieberman R, La Rocca RV, et al. Adaptive control with feedback strategies for suramin dosing. Clin Pharmacol Ther 1992,52, 11-23.
7. Wittes RE, ed. Manual of Oncologic Therapeutics: Appendix A. Grading of Toxicity. Philadelphia, JB Lipincott Co, 1989, 627-632.
8. Supko JG, Malspeis L. A rapid isocratic HPLC assay of suramin in human plasma. J Liq Chromatogr 1993, 13, 727-741.
9. Hoagland HC. Hématologie complications of cancer chemotherapy. In Perry MC, Yarboro JW, eds. Toxicity of Chemotherapy. New York, Grune & Stratton, Inc, 1984, 433-448.
10. Foon KA. The cytokine network. Oncology 1993, 7, 11-15.
11. Doukas M, Chavan A, Gass C, et al. Inhibition of granulocytemacrophage colony-stimulating factor (GM-CSF) activity by suramin and suramin analogues is correlated to interaction with the GM-CSF nucleotide-binding site. Cancer Res 1995, 55, 5161-5163.
12. Collins JM, Klecker RW Jr, Yarchoan R, et al. Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection. J Clin Pharmacol 1986, 22, 22-26.